Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Internal Medicine›Condition·Updated Apr 17, 2026·v1

Cushing Syndrome

Cushing syndrome is a complex endocrine disorder of chronic hypercortisolism that requires a stepwise diagnostic approach: confirmation of the biochemical state, followed by ACTH-based differentiation, and finally anatomical localization. Surgery is the definitive treatment, but medical management and aggressive supportive care for metabolic and thrombotic risks are essential for reducing high baseline mortality.

High Evidence82 references·2,744 words·11 min read·v1
EndocrinologyHypercortisolismPituitary AdenomaAdrenal IncidentalomaHypertension

Quick Reference

RxDrug of choiceOsilodrostat (medical); Hydrocortisone (post-op replacement)
AltAlternativesKetoconazole, Metyrapone, Mifepristone
⊘AvoidRapid withdrawal of steroids without replacement; Ketoconazole in severe liver disease
DxTest of choice1-mg Dexamethasone Suppression Test (screening); IPSS (localization)
ScKey scorePadua Prediction Score (for VTE risk)
→When to referRefer all suspected cases to Endocrinology for biochemical confirmation and localization.
Cushing syndrome is a life-threatening state of cortisol excess requiring surgical cure; medical therapy and VTE prophylaxis are vital adjuncts.
Cushing syndrome (CS) is a high-morbidity clinical state resulting from chronic, pathological exposure to excessive circulating glucocorticoids. It is broadly classified into ACTH-dependent forms (80-85%), primarily caused by pituitary adenomas (Cushing disease) or ectopic neuroendocrine tumors, and ACTH-independent forms (15-20%), typically arising from adrenal adenomas or carcinomas. The condition is characterized by a multisystemic impact, including resistant hypertension, type 2 diabetes, severe osteoporosis, and immune suppression. Early recognition is critical, as untreated hypercortisolism carries a high mortality risk from cardiovascular events and opportunistic infections. Management focuses on the rapid normalization of cortisol levels, primarily through surgical resection of the offending lesion, supplemented by medical steroidogenesis inhibitors and aggressive supportive care for metabolic and thrombotic complications.

Overview and Recommendations

Background

  • •Define Cushing syndrome as the clinical manifestation of chronic hypercortisolism, which must be distinguished from iatrogenic causes (exogenous steroid use) and pseudo-Cushing states (e.g., severe obesity, chronic alcoholism, or major depression).
  • •Distinguish between (CD), which refers specifically to a pituitary ACTH-secreting adenoma, and the broader Cushing syndrome, which includes adrenal and ectopic sources.
  • •Recognize the high prevalence of mild autonomous cortisol secretion (MACS) in patients with adrenal incidentalomas (4-7% of the population over age 40), where subtle cortisol excess increases cardiometabolic risk without classic physical stigmata.
  • •Identify the two main pathophysiological categories: ACTH-dependent (pituitary or ectopic) and ACTH-independent (adrenal adenoma, carcinoma, or bilateral hyperplasia), as this distinction dictates the entire diagnostic workup.
  • •Note the significant female predominance (up to 3:1) in endogenous Cushing syndrome, with a peak incidence typically occurring between the ages of 30 and 50 years.
  • •Understand the urgency of identifying 'Cushing's Crisis,' an endocrine emergency characterized by severe hypertension, profound hypokalemia, and acute psychosis, often seen in aggressive ectopic ACTH-secreting tumors.

Evaluation

  • •Suspect Cushing syndrome in patients with 'red flag' features: proximal muscle weakness (difficulty climbing stairs), wide (>1 cm) purple striae, facial plethora, and supraclavicular fat pads, especially when these coexist with resistant hypertension or early-onset osteoporosis.
  • •Screen high-risk populations even in the absence of classic signs, including those with difficult-to-control type 2 diabetes, hypertension requiring >3 medications, or adrenal incidentalomas discovered on imaging.
  • •Rule out exogenous glucocorticoid use by taking a meticulous history of oral, inhaled, topical, and injectable steroids, including 'herbal' supplements that may be adulterated with dexamethasone.
  • •Perform initial biochemical screening using one of three validated tests: a 24-hour urinary free cortisol (UFC), a late-night salivary cortisol (LNSC), or a 1-mg overnight suppression test (DST).
  • •Interpret the 1-mg DST using a strict threshold: a serum cortisol >1.8 µg/dL (50 nmol/L) is considered a positive screen and requires further confirmatory testing.
  • •Confirm the diagnosis with a second, different screening test if the initial result is abnormal, as cyclic Cushing syndrome or false positives from stress/medications can occur.
  • •Measure plasma ACTH levels once hypercortisolism is confirmed; levels <5 pg/mL indicate ACTH-independent (adrenal) disease, while levels >20 pg/mL indicate ACTH-dependent disease.
  • •Order a non-contrast CT of the adrenal glands if ACTH is suppressed to identify unilateral adenomas, large irregular masses suggestive of adrenal cortical carcinoma, or bilateral nodular hyperplasia.
  • •Order a gadolinium-enhanced MRI of the pituitary if ACTH is elevated; however, be aware that up to 40% of corticotroph microadenomas are too small to be visualized on standard imaging.
  • •Perform Inferior Petrosal Sinus Sampling (IPSS) with CRH or desmopressin stimulation if the pituitary MRI is negative or shows a lesion <6 mm, as this is the gold standard for differentiating CD from .
  • •Evaluate for ectopic sources using high-resolution CT of the chest and abdomen or functional imaging (e.g., 68Ga-DOTATATE PET/CT) if IPSS suggests a non-pituitary source of ACTH.
  • •Assess for complications at diagnosis, including a baseline DXA scan for bone density, screening for glucose intolerance, and a Padua Prediction Score for venous thromboembolism risk.

Management

  • •Prioritize surgical resection of the primary tumor as the first-line treatment for all forms of endogenous Cushing syndrome, aiming for a complete biochemical cure.
  • •Perform transsphenoidal surgery (TSS) for Cushing Disease, ideally by a high-volume pituitary surgeon, as initial remission rates are approximately 70-90% for microadenomas.
  • •Execute a unilateral laparoscopic adrenalectomy for cortisol-secreting adrenal adenomas, which typically results in a permanent cure but requires postoperative steroid replacement.
  • •Stabilize patients with Severe Cushing Syndrome (UFC >5x upper limit of normal) using parenteral Etomidate at a non-hypnotic dose of 0.03 mg/kg/hour IV, titrated to maintain serum cortisol between 500-800 nmol/L.
  • •Initiate medical therapy with Osilodrostat (an 11β-hydroxylase inhibitor) starting at 2 mg BID, titrating every 1-2 weeks, for patients with persistent disease after surgery or those who are not surgical candidates.
  • •Utilize Ketoconazole 200 mg TID (monitoring LFTs weekly) or Metyrapone 250 mg TID as alternative steroidogenesis inhibitors to achieve rapid biochemical control.
  • •Administer Mifepristone 300-900 mg once daily for patients with hypercortisolism and type 2 diabetes; note that this drug blocks the glucocorticoid receptor and will increase circulating cortisol levels, making biochemical monitoring difficult.
  • •Start thromboprophylaxis with Enoxaparin 40 mg SC daily immediately upon diagnosis of overt Cushing syndrome and continue for at least 3 months post-surgery to mitigate the 18-fold increased risk of VTE.
  • •Manage glucocorticoid-induced osteoporosis with Alendronate 70 mg PO weekly or Zoledronic acid 5 mg IV annually, alongside Calcium 1200 mg and Vitamin D 2000 IU daily.
  • •Implement immediate postoperative glucocorticoid replacement with Hydrocortisone 15-25 mg/day in divided doses (e.g., 10mg-5mg-5mg) to prevent adrenal crisis, as the contralateral adrenal or normal pituitary cells will be suppressed.
  • •Monitor for 'steroid withdrawal syndrome'—characterized by severe joint pain, fatigue, and desquamation—which can occur even when replacement doses are physiologically appropriate.
  • •Treat comorbid hypertension aggressively with ACE inhibitors or mineralocorticoid receptor antagonists (e.g., Spironolactone) if hypokalemia is present due to mineralocorticoid receptor crossover.
  • •Refer patients with refractory Cushing Disease for pituitary radiotherapy or bilateral adrenalectomy if surgical and medical options fail, noting the risk of Nelson Syndrome (pituitary tumor progression) after adrenalectomy.
  • •Discharge patients only after they are educated on 'sick day rules' for adrenal insufficiency and have a prescription for an emergency hydrocortisone injection kit.

Board Review — High Yield

  • •Proximal muscle weakness — The most specific physical finding for Cushing syndrome compared to simple obesity.
  • •Hypokalemic metabolic alkalosis — Highly suggestive of Ectopic ACTH Syndrome or Adrenal Cortical Carcinoma due to mineralocorticoid effects.
  • •1.8 µg/dL — The serum cortisol cutoff for a 'pass' on the 1-mg Dexamethasone Suppression Test.
  • •Inferior Petrosal Sinus Sampling (IPSS) — The gold standard to distinguish a pituitary source (Cushing Disease) from an ectopic source.
  • •Nelson Syndrome — Rapid enlargement of a pituitary corticotroph adenoma and hyperpigmentation following bilateral adrenalectomy.
  • •Hyperpigmentation — Occurs only in ACTH-dependent forms (CD or EAS) due to MSH-like activity of ACTH precursors.
  • •ARMC5 mutation — Associated with Primary Bilateral Macronodular Adrenal Hyperplasia (PBMAH).
  • •24-hour UFC — Can be falsely low in patients with renal impairment (GFR <30 mL/min).

Deep Dive — Evidence Details

References

  1. [1]

    Nowak E, Viëtor CL, Feelders RA et al.. “Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study.” The lancet. Diabetes & endocrinology (2026). PMID: 41579871 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors
  2. [2]

    Nowak E, Zhang Q, Zhang S et al.. “Cycle characterisation and clinical complications in patients with cyclic Cushing's syndrome: insights from an international retrospective cohort study.” The lancet. Diabetes & endocrinology (2025). PMID: 41235993 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification
  3. [3]

    Swart CC, de Krijger RR. “Histopathological and Molecular Characteristics of Pediatric Adrenocortical Tumors: where Do we Stand?” Endocrine pathology (2026). PMID: 41712100 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors
  4. [4]

    Kaniuka-Jakubowska S, Kunc M, Maksymowicz M et al.. “A case of prolonged adrenal insufficiency following osilodrostat discontinuation with a review of the literature.” Endocrine journal (2026). PMID: 41139506 ↗

    L4CASE_REPORTCited in: Definition, Synonyms, and Classification
  5. [5]

    Krzystek Ł, Sagan KP, Andrysiak-Mamos E et al.. “Case Report: Ectopic Cushing's syndrome caused by a pancreatic neuroendocrine tumor managed through dual steroidogenesis inhibition and endoscopic ultrasound-guided ethanol ablation.” Frontiers in endocrinology (2025). PMID: 41488150 ↗

    L4CASE_REPORTCited in: Definition, Synonyms, and Classification, Management
  6. [6]

    Tanaka M, Uejima M, Ozaki K et al.. “Role of 68Ga-DOTATOC Positron Emission Tomography in Locating Pulmonary Neuroendocrine Tumor Presenting with ACTH-Dependent Cushing's Syndrome: A Case Report.” Journal of clinical medicine (2025). PMID: 41464537 ↗

    L4CASE_REPORTCited in: Definition, Synonyms, and Classification
  7. [7]

    Varlamov EV, Park BJ, Fleseriu M. “Osilodrostat-associated Adrenal Gland Shrinkage: A Case Series of Patients With ACTH-dependent Cushing's Syndrome.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41054820 ↗

    L4CASE_REPORTCited in: Definition, Synonyms, and Classification, Management
  8. [8]

    Pokrzywa A, Pachucki J, Bobrowicz M et al.. “Case Report: Ectopic CRH production by adrenal adenoma as a unique cause of the ACTH-dependent Cushing's syndrome.” Frontiers in endocrinology (2025). PMID: 40927294 ↗

    L4CASE_REPORTCited in: Definition, Synonyms, and Classification
  9. [9]

    Weismann D. “[Endocrine emergencies].” Medizinische Klinik, Intensivmedizin und Notfallmedizin (2026). PMID: 41805972 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  10. [10]

    Mosquera JE, Rahimi L, Hamidi O. “Advances in the medical management of hypercortisolism: current strategies, monitoring, and emerging therapies.” Current opinion in endocrinology, diabetes, and obesity (2025). PMID: 40709385 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Supportive Care and Complication Management
  11. [11]

    Gür EÖ, Karaıslı S, Çavdar Ü et al.. “Genetic background and management outcomes in primary bilateral macronodular adrenal hyperplasia: Implications for diagnosis and treatment-A retrospective cohort study.” The Journal of international medical research (2026). PMID: 41871980 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification, Management
  12. [12]

    Rivera Martínez WA, Builes-Montaño CE, Henao NA et al.. “Predictive model for the diagnosis of Ectopic Cushing Syndrome.” Endocrine-related cancer (2026). PMID: 41989874 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  13. [13]

    Köroğlu EY, Tam AA, Faki S et al.. “Diagnostic Utility of ACTH, Cortisol, DHEAS, and Their Derived Ratios in Cushing's Syndrome Subtypes.” Journal of clinical medicine (2026). PMID: 41977073 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  14. [14]

    Liu J, Zhou X, Zhu H et al.. “Circulating immune profiles in ACTH-dependent Cushing's syndrome.” European journal of endocrinology (2026). PMID: 41934628 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors
  15. [15]

    Rivera-Martínez WA, Ramírez Castaño MJ, Cruz Calderón S et al.. “Clinical characteristics, diagnosis, and treatment of Cushing's syndrome: analysis of a multicenter registry in Antioquia, Colombia.” Therapeutic advances in endocrinology and metabolism (2026). PMID: 41919182 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors
  16. [16]

    Parisien-La Salle S, Tsai CH, Newman AJ et al.. “Unmasking Hormonal Mechanisms of Hypertension in Obesity.” JACC. Basic to translational science (2026). PMID: 41864192 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  17. [17]

    Zhang Z, Li C, Xiao Y et al.. “The value of 68Ga-Pentixafor PET/CT targeting CXCR4 in the diagnosis of ACTH-independent Cushing syndrome.” Hypertension research : official journal of the Japanese Society of Hypertension (2026). PMID: 41639350 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  18. [18]

    Koumarianou A, Derks J, Tsoli M et al.. “LUNG CARCINOIDS (Lung Neuroendocrine Tumors).” Endocrine reviews (2026). PMID: 41526992 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors
  19. [19]

    Losa M, Loli P, Nocera G et al.. “A positive corticotropin-releasing hormone test may obviate the need for petrosal sinus sampling in patients with cushing's disease.” Journal of endocrinological investigation (2026). PMID: 41493525 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  20. [20]

    Vaduva P, Violon F, Chansavang A et al.. “PRKACA constitutional duplication: a specific cause of primary pigmented nodular adrenocortical disease.” European journal of endocrinology (2025). PMID: 41403049 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  21. [21]

    Huang C, Chang LY, Sheu JY et al.. “Exploring the high prevalence, comorbidities, and indicators of mild autonomous cortisol secretion in primary aldosteronism: a cohort study and systematic review.” Hypertension research : official journal of the Japanese Society of Hypertension (2025). PMID: 40069399 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  22. [22]

    Zhou Z, Yin Z, Miao H et al.. “Screening for endocrine hypertension in China: protocol for a multicentre prospective cohort study.” BMJ open (2025). PMID: 40887111 ↗

    L2bTRIAL_NONRANDOMCited in: Epidemiology and Risk Factors
  23. [23]

    Sharon Y, Shochat T, Rudman Y et al.. “Cushing's syndrome related to higher rates and earlier onset of cataract: A nationwide retrospective cohort study.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2025). PMID: 39847049 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors
  24. [24]

    Kvapil T, Kociánová E, Ramík Z et al.. “Secondary causes and renal outcomes in apparently resistant hypertension: a retrospective cohort study.” Blood pressure (2026). PMID: 41504217 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors
  25. [25]

    Al-Omari AA, Obeidat N, Alnemer AF et al.. “Is there a relationship between lumbosacral epidural spinal injections and lumbosacral epidural lipomatosis? A retrospective study.” Neuro-Chirurgie (2025). PMID: 39800218 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors
  26. [26]

    Wonglhaw W, Santi-Ngamkun A, Ratchanon S et al.. “Cardiovascular risk improvement after laparoscopic adrenalectomy in patients with cortisol-secreting adrenal adenoma, a retrospective cohort study.” Gland surgery (2024). PMID: 39678424 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors
  27. [27]

    Minasyan M, Suchy W, Fedak A et al.. “Liver impairment and medical management of Cushing syndrome and MACS.” Frontiers in endocrinology (2025). PMID: 41210495 ↗

    L4CASE_REPORTCited in: Epidemiology and Risk Factors, Management
  28. [28]

    Kattah L, Bustamante L, Sanabria D et al.. “Case Report: Refractory hypokalemia as a clinical manifestation of Crooke's cell adenoma.” Frontiers in medicine (2025). PMID: 40636382 ↗

    L4CASE_REPORTCited in: Epidemiology and Risk Factors
  29. [29]

    Mirsharifi SA, Nasiri S, Tavangar SM et al.. “Clinical Outcomes and Predictive Factors in Adrenalectomy: A Retrospective Cohort Study.” Iranian journal of pathology (2026). PMID: 41624739 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors
  30. [30]

    Snyder CN, Frontera ED, Meng J et al.. “Potential mechanisms of the glucocorticoid withdrawal syndrome.” European journal of endocrinology (2026). PMID: 41988948 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  31. [31]

    Piórek A, Płużański A, Kowalski DM et al.. “Clinicopathologic Characteristics, Treatment Outcomes, and Survival in Thymic Neuroendocrine Neoplasms (t-NEN): A 25-Year Single-Center Experience.” Cancers (2025). PMID: 41463183 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  32. [32]

    Musolino A, Parazzoli C, Delle Donne E et al.. “Prevalence of Hypercortisolism in Hypertension and Its Link to Carotid Atherosclerosis Markers.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2026). PMID: 41167561 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  33. [33]

    Yoshida K, Kobatake Y, Takashima S et al.. “Risk Factors for Pituitary Macrotumor in Dogs With Hypercortisolism.” Journal of veterinary internal medicine (2025). PMID: 41014092 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  34. [34]

    Mirica A, Tilici DM, Paun DL et al.. “Adrenal Incidentaloma: From Silent Diagnosis to Clinical Challenge.” Biomedicines (2025). PMID: 41007858 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  35. [35]

    Prinzi A, Lombardo AM, Finocchiaro S et al.. “Expanding the Clinical Profile of Mild Autonomous Cortisol Secretion: New Diagnostic Markers and Emerging Complications.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2026). PMID: 40972722 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  36. [36]

    Mondin A, Barbot M, Ceccato F et al.. “European survey on metabolic and cardiovascular risk in Cushing syndrome.” Journal of endocrinological investigation (2025). PMID: 40913679 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  37. [37]

    Trandafir AI, Carsote M, Florescu AF. “An Analysis of Post-Adrenalectomy Dynamics in MACS (Mild Autonomous Cortisol Secretion)-Positive Adrenal Tumours: The Biomarkers and Clinical Impact.” Journal of clinical medicine (2025). PMID: 40806839 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  38. [38]

    Ritzel K, Fedtke V, Then C et al.. “Hypertension and kidney dysfunction despite long-term remission of Cushing's syndrome.” Journal of endocrinological investigation (2025). PMID: 40728707 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  39. [39]

    DeFronzo RA, Auchus RJ. “Cushing Syndrome, Hypercortisolism, and Glucose Homeostasis: A Review.” Diabetes (2025). PMID: 40663715 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  40. [40]

    Pellegrini B, Bonaventura I, Hasenmajer V et al.. “Adrenal causes of endocrine hypertension in childhood or adolescence.” Journal of endocrinological investigation (2025). PMID: 40540150 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  41. [41]

    DeFronzo RA, Fonseca V, Aroda VR et al.. “Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.” Diabetes care (2025). PMID: 40550011 ↗

    L1bRCTCited in: Management
  42. [42]

    Nieman LK, Boscaro M, Scaroni C et al.. “Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT).” European journal of endocrinology (2025). PMID: 40966724 ↗

    L2bTRIAL_NONRANDOMCited in: Management
  43. [43]

    DeFronzo RA, Auchus RJ, Bancos I et al.. “Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone.” BMJ open (2024). PMID: 39013654 ↗

    L2bTRIAL_NONRANDOMCited in: Management
  44. [44]

    Pivonello R, Fleseriu M, Newell-Price J et al.. “Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease.” Journal of endocrinological investigation (2024). PMID: 38696122 ↗

    L2bTRIAL_NONRANDOMCited in: Management
  45. [45]

    Salvio G, Ciarloni A, Aboud N et al.. “The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41432529 ↗

    L2aSR_OBSCited in: Management
  46. [46]

    Ren X, Nan M, Zhang X. “Evaluating the efficacy of surgical and conservative approaches in mild autonomous cortisol secretion: a meta-analysis.” Frontiers in endocrinology (2024). PMID: 39086899 ↗

    L2aSR_OBSCited in: Management
  47. [47]

    Sun J, Ding L, He L et al.. “The clinical characteristics and pathogenic variants of primary pigmented nodular adrenocortical disease in 210 patients: a systematic review.” Frontiers in endocrinology (2024). PMID: 39006359 ↗

    L2aSR_OBSCited in: Management, Supportive Care and Complication Management
  48. [48]

    Khadembashiri MM, Mohseni S, Harandi H et al.. “Comparison of adrenalectomy with conservative treatment on mild autonomous cortisol secretion: a systematic review and meta-analysis.” Frontiers in endocrinology (2024). PMID: 38808111 ↗

    L2aSR_OBSCited in: Management, Supportive Care and Complication Management
  49. [49]

    Hamidi O, Shah M, Zhang CD et al.. “Clinical and imaging presentations are associated with function in incidental adrenocortical adenomas: a retrospective cohort study.” European journal of endocrinology (2024). PMID: 38941271 ↗

    L2bCOHORTCited in: Management
  50. [50]

    Araujo-Castro M, García-Centeno R, Aller J et al.. “Executive summary of the consensus document for the management of severe Cushing's syndrome: Consensus document of the Neuroendocrinology Focus Group of the Spanish Society of Endocrinology and Nutrition (SEEN).” Endocrinologia, diabetes y nutricion (2025). PMID: 41419261 ↗

    L1cGUIDELINECited in: Management
  51. [51]

    Isand K, Wass J, Karavitaki N et al.. “Approach to the Patient with Cushing's Syndrome: Use of Anticoagulation Therapy.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41396880 ↗

    L4CASE_REPORTCited in: Management, Supportive Care and Complication Management
  52. [52]

    Aldhoon-Hainerová I, Kosák M, Kršek M et al.. “Ectopic adrenocorticotrophic hormone syndrome in a 10-year-old girl with a thymic neuroendocrine tumor: a case report.” BMC endocrine disorders (2024). PMID: 39538188 ↗

    L4CASE_REPORTCited in: Management
  53. [53]

    Corica D, Corica D, Lugarà C et al.. “Adrenal Cushing Syndrome: Diagnosis and Management in a 10-Year-Old Boy with Carney Complex.” Hormone research in paediatrics (2025). PMID: 39102796 ↗

    L4CASE_REPORTCited in: Management
  54. [54]

    Ertl DA, Ratzinger-Stoeger G, Raimann A et al.. “Successful Use of Metyrapone Suppositories in an Infant with Neonatal Cushing and McCune Albright Syndrome: A Case Report.” Hormone research in paediatrics (2025). PMID: 38008082 ↗

    L4CASE_REPORTCited in: Management
  55. [55]

    Tan L, Zhao L, Tang G et al.. “Unexpected exacerbation of cryptococcal meningitis after unilateral adrenalectomy in a PMAH patient: a case report and literature review.” BMC endocrine disorders (2023). PMID: 37723545 ↗

    L4CASE_REPORTCited in: Management
  56. [56]

    Unsal Y, Gozmen O, User İR et al.. “Case Report: Severe McCune-Albright syndrome presenting with neonatal Cushing syndrome: navigating through clinical obstacles.” Frontiers in endocrinology (2023). PMID: 37560302 ↗

    L4CASE_REPORTCited in: Management
  57. [57]

    Jawanjal AB, Sadananda S, Sriramaneni N et al.. “Demographic and Clinical Characteristics of Patients with Adrenal Incidentaloma from a Single Center in South India: A Retrospective Study.” Annals of African medicine (2024). PMID: 39164941 ↗

    L2bCOHORTCited in: Management
  58. [58]

    Ibrahimli A, Memisoglu E, Perez-Soto R et al.. “Steroid replacement after adrenalectomy for mild autonomous cortisol secretion: Clinical predictors and a practical algorithm.” Surgery (2026). PMID: 41407599 ↗

    L5OTHERCited in: Management
  59. [59]

    Taylor GA, Allen M, Lisevick Kumar A et al.. “Adrenalectomy patients with mixed primary aldosteronism and hypercortisolism: An analysis of outcomes following surgery at a single institution.” Surgery (2026). PMID: 41371823 ↗

    L5OTHERCited in: Management
  60. [60]

    Laffi A, Prinzi A, Di Dato C et al.. “Clinical management of ectopic Cushing Syndrome in neuroendocrine neoplasms: a national survey.” Frontiers in endocrinology (2025). PMID: 41282293 ↗

    L5OTHERCited in: Management
  61. [61]

    Musolino A, Favero V, Parazzoli C et al.. “Effects of metyrapone in patients with mild hypercortisolism.” European journal of endocrinology (2025). PMID: 41102583 ↗

    L5OTHERCited in: Management
  62. [62]

    Piazzola C, Castinetti F, von Fabeck K et al.. “A preliminary model to tailor osilodrostat in patients with Adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome.” European journal of endocrinology (2025). PMID: 40971972 ↗

    L5OTHERCited in: Management
  63. [63]

    Manyalich-Blasi M, Saavedra-Pérez D, Guzman LMF et al.. “Robotic posterior retroperitoneoscopic adrenalectomy: initial experience with Hugo™ RAS system.” Journal of robotic surgery (2025). PMID: 40523980 ↗

    L5OTHERCited in: Management
  64. [64]

    Hickey C, Gueron B, Schmidt F et al.. “Matching-Adjusted Indirect Comparison of Osilodrostat Versus Metyrapone for the Treatment of Cushing's Syndrome.” Advances in therapy (2025). PMID: 40439958 ↗

    L5OTHERCited in: Management
  65. [65]

    Ferrari D, Bonaventura I, Simeoli C et al.. “Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40172910 ↗

    L5OTHERCited in: Management
  66. [66]

    Nieman LK, Castinetti F, Newell-Price J et al.. “Cushing syndrome.” Nature reviews. Disease primers (2025). PMID: 39848955 ↗

    L5REVIEW_NARRATIVECited in: Management
  67. [67]

    Ceccato F, Terzolo M, Gatto F et al.. “Who and how to screen for Cushing's syndrome: the position statement of the Italian Society of Endocrinology.” Journal of endocrinological investigation (2026). PMID: 41364328 ↗

    L1cGUIDELINECited in: Supportive Care and Complication Management
  68. [68]

    Braun LT, Vogel F, Zopp S et al.. “Whom Should We Screen for Cushing Syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35730067 ↗

    L1cGUIDELINECited in: Supportive Care and Complication Management
  69. [69]

    Charoenngam N, Rittiphairoj T, Plessias C et al.. “Bone Mineral Density Improvement After Resolution of Endogenous Cushing Syndrome: A Systematic Review and Meta-Analysis.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025). PMID: 39689783 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  70. [70]

    Katragadda A, Kunadia J, Kirsch P et al.. “Cognitive decline in Cushing's syndrome: A systematic review.” Journal of neuroendocrinology (2025). PMID: 39506264 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  71. [71]

    Pal R, Banerjee M, Prasad TN et al.. “Fracture risk and bone health in adrenal adenomas with mild autonomous cortisol secretion/subclinical hypercortisolism: a systematic review, meta-analysis and meta-regression.” Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2024). PMID: 38703381 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  72. [72]

    Kuckuck S, Lengton R, Boon MR et al.. “Long-term glucocorticoids in relation to the metabolic syndrome and cardiovascular disease: A systematic review and meta-analysis.” Journal of internal medicine (2024). PMID: 37926862 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  73. [73]

    Puglisi S, Perini AME, Botto C et al.. “Long-Term Consequences of Cushing Syndrome: A Systematic Literature Review.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37536275 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  74. [74]

    Lhul RVDS, Nunes KG, Almeida TS et al.. “Cushing's syndrome: a systematic review of psychiatric and cognitive symptoms in case studies.” Archives of endocrinology and metabolism (2026). PMID: 41945628 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  75. [75]

    Remde H, Kranz S, Morell SM et al.. “Clinical course of patients with adrenal incidentalomas and cortisol autonomy: a German retrospective single center cohort study.” Frontiers in endocrinology (2023). PMID: 37223045 ↗

    L2bCOHORTCited in: Supportive Care and Complication Management
  76. [76]

    Giordano R, Parasiliti Caprino M, Loli P et al.. “Screening for endogenous hypercortisolism in patients with osteoporosis and fractures: why, when and how.” Journal of endocrinological investigation (2025). PMID: 39361239 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  77. [77]

    Bryk-Wiązania AH, Minasyan M, Świątkowska-Stodulska R et al.. “The thrombotic risk in Cushing's syndrome-questions, answers, and the algorithm to consider in its assessment: part I-thrombotic risk not related to surgery.” Frontiers in endocrinology (2024). PMID: 38529392 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  78. [78]

    Courcelles L, Stoenoiu M, Haufroid V et al.. “Laboratory Testing for Endocrine Hypertension: Current and Future Perspectives.” Clinical chemistry (2024). PMID: 38484135 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  79. [79]

    Cheng J, Ju S, Zhang Z. “Osteoporotic vertebral compression fractures caused by Cushing's syndrome in young women: case report and literature review.” BMC musculoskeletal disorders (2023). PMID: 36879208 ↗

    L4CASE_REPORTCited in: Supportive Care and Complication Management
  80. [80]

    Tang P, Zhang J, Peng S et al.. “Primary bilateral macronodular adrenocortical hyperplasia (PBMAH) patient with ARMC5 mutations.” BMC endocrine disorders (2023). PMID: 37029354 ↗

    L4CASE_REPORTCited in: Supportive Care and Complication Management
  81. [81]

    Araujo-Castro M, Pascual-Corrales E, Lamas C. “Possible, probable, and certain hypercortisolism: A continuum in the risk of comorbidity.” Annales d'endocrinologie (2023). PMID: 36736771 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  82. [82]

    Feelders RA, Nieman LK. “Hypercoagulability in Cushing's syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols.” Pituitary (2022). PMID: 35881275 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management

Revision History

All updates applied to this page

Loading revisions…